Hermansky-Pudlak Syndrome (HPS) is a rare genetic disease that is associated with oculocutaneous albinism, bleeding, granulomatous colitis, and pulmonary fibrosis in some subtypes, including HPS-1, HPS-2, and HPS-4. Pulmonary fibrosis causes shortness of breath and progressive decline in lung function. In HPS patients with at-risk subtypes, almost all adults eventually develop fatal pulmonary fibrosis unless they undergo lung transplantation. The purpose of this study is to identify the earliest measurable pulmonary disease activity in individuals at-risk for HPS pulmonary fibrosis. The study also aims to develop biomarkers that will aid in understanding of the causes of HPS pulmonary fibrosis and facilitate more rapid conduct of therapeutic trials in HPS patients with mild pulmonary disease in the future.
Study Type
OBSERVATIONAL
Enrollment
55
Pulmonary function testing performed
Chest CT scan to evaluate for pulmonary fibrosis
Blood and urine sample collections
Loyola University Medical Center
Maywood, Illinois, United States
Brigham and Women's Hospital, Harvard
Boston, Massachusetts, United States
Columbia University Medical Center
New York, New York, United States
Children's Hospital of Philadelphia
Philadelphia, Pennsylvania, United States
Vanderbilt University
Nashville, Tennessee, United States
Chest CT scan
Time frame: change in CT Scan from baseline to 2.5 years
Pulmonary function test
Time frame: change in PFTs from baseline to 2.5 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.